SERO’s Derek McHaffie Presented Radium 223 Dichloride in Treatment of Castration Resistant Metastatic Prostate Cancer

Posted on October 16, 2014 in Prostate Cancer

Written by Dr. McHaffie

Learn more about the author

SERO’s Derek McHaffie Presented Radium 223 Dichloride in Treatment of Castration Resistant Metastatic Prostate Cancer

Derek McHaffie, MD, a SERO physician with expertise across the spectrum of prostate cancer care, presented retrospective data from the Levine Cancer Institute’s experience with Radium 223 Dichloride (Xofigo) in the treatment of castration resistant metastatic prostate cancer at the 56th annual meeting of the American Society of Radiation Oncology in San Francisco, CA. For a thorough understanding of Prostate Cancer, get our eBook.

SERO’s Derek McHaffie Presented Radium 223 Dichloride in Treatment of Castration Resistant Metastatic Prostate Cancer